Published in Nature on April 28, 2005
Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89
Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood (2006) 8.56
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature (2009) 4.60
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood (2009) 4.22
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia (2010) 4.09
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol (2011) 4.06
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood (2008) 3.89
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature (2009) 3.80
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood (2013) 3.78
Janus kinases in immune cell signaling. Immunol Rev (2009) 3.60
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med (2013) 3.57
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 3.47
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell (2010) 3.46
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood (2010) 3.41
Myeloproliferative disorders. Blood (2008) 3.37
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood (2005) 3.24
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet (2009) 3.21
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet (2009) 3.10
Making sense of cancer genomic data. Genes Dev (2011) 3.01
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet (2009) 3.00
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A (2005) 2.94
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A (2006) 2.94
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood (2010) 2.83
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res (2010) 2.69
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia (2010) 2.65
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
The molecular mechanisms that control thrombopoiesis. J Clin Invest (2005) 2.48
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol (2009) 2.43
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One (2006) 2.42
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov (2011) 2.38
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood (2006) 2.38
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood (2008) 2.37
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood (2007) 2.31
Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity (2012) 2.30
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia (2014) 2.28
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol (2011) 2.20
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood (2010) 2.16
Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood (2006) 2.16
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood (2007) 2.09
X-linked clonality testing: interpretation and limitations. Blood (2007) 2.04
Therapeutic targeting of Janus kinases. Immunol Rev (2008) 2.03
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res (2012) 2.01
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia (2013) 1.97
3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood (2011) 1.96
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest (2010) 1.93
Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol (2009) 1.92
Class prediction models of thrombocytosis using genetic biomarkers. Blood (2009) 1.92
Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest (2008) 1.89
Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia. Nat Med (2013) 1.89
SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS One (2007) 1.87
Unrestrained erythroblast development in Nix-/- mice reveals a mechanism for apoptotic modulation of erythropoiesis. Proc Natl Acad Sci U S A (2007) 1.86
Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol (2008) 1.85
A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood (2011) 1.84
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol (2009) 1.83
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood (2010) 1.83
Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion. PLoS Biol (2013) 1.82
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood (2009) 1.82
RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A (2009) 1.81
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia (2008) 1.79
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood (2014) 1.79
Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell (2009) 1.78
Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell (2010) 1.78
Pseudokinases-remnants of evolution or key allosteric regulators? Curr Opin Struct Biol (2010) 1.76
Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program (2009) 1.74
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol (2010) 1.69
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood (2014) 1.68
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med (2012) 1.65
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol (2009) 1.64
The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood (2009) 1.63
Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood (2005) 1.63
Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc (2010) 1.63
SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet (2008) 1.62
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res (2013) 1.59
Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood (2007) 1.55
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem (2006) 1.55
Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood (2014) 1.55
Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood (2014) 1.53
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia (2011) 1.53
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood (2012) 1.52
JAK2(V617F): Prevalence in a large Chinese hospital population. Blood (2006) 1.50
Defining the blueprint of the cancer genome. Carcinogenesis (2008) 1.49
Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol (2008) 1.48
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nat Biotechnol (2008) 7.91
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell (2011) 5.28
Metastable pluripotent states in NOD-mouse-derived ESCs. Cell Stem Cell (2009) 3.92
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med (2009) 3.37
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood (2006) 3.37
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood (2008) 3.30
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol (2013) 3.10
Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. Nat Biotechnol (2008) 2.84
Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A (2009) 2.80
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood (2009) 2.77
Platelet formation is the consequence of caspase activation within megakaryocytes. Blood (2002) 2.62
NetPath: a public resource of curated signal transduction pathways. Genome Biol (2010) 2.62
New mutations and pathogenesis of myeloproliferative neoplasms. Blood (2011) 2.53
Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol (2011) 2.50
Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int (2012) 2.38
JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol (2008) 2.37
Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park) (2010) 2.22
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood (2008) 2.21
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH). Blood (2002) 2.17
Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells. Development (2002) 2.16
A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. Blood (2009) 2.08
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
Apoptosis regulation in tetraploid cancer cells. EMBO J (2006) 1.89
Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry (2006) 1.88
NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood (2004) 1.88
Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood (2002) 1.84
Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell (2003) 1.84
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood (2007) 1.83
Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol (2004) 1.81
Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene (2004) 1.79
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood (2008) 1.77
JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem (2005) 1.74
Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion (2008) 1.73
Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation. Blood (2010) 1.73
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood (2006) 1.71
MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. Blood (2009) 1.70
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood (2011) 1.68
Clonal architecture of chronic myelomonocytic leukemias. Blood (2013) 1.67
Molecular aspects of myeloproliferative neoplasms. Int J Hematol (2010) 1.67
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood (2007) 1.66
Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood (2010) 1.64
Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process. Blood (2010) 1.63
Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. Blood (2008) 1.61
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood (2007) 1.61
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood (2012) 1.59
An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med (2009) 1.58
Transfer of differentiation signal by membrane microvesicles harboring hedgehog morphogens. Blood (2006) 1.58
Activating mutations in human acute megakaryoblastic leukemia. Blood (2008) 1.56
Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. Nephrol Dial Transplant (2006) 1.56
Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood (2006) 1.56
High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood (2006) 1.55
Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J Biol Chem (2008) 1.54
Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. Blood (2013) 1.52
Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4-/- chimeric mice. Blood (2005) 1.51
Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. Haematologica (2007) 1.51
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood (2005) 1.50
Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood (2006) 1.50
The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood (2008) 1.48
The cell cycle regulator CDC25A is a target for JAK2V617F oncogene. Blood (2011) 1.47
Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood (2009) 1.47
Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol (2004) 1.46
Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood (2002) 1.45